Amgen Hones In On Denosumab Sales And Payer Strategies Ahead Of Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech estimates 500 to 1,000 sales reps will be needed to commercialize the osteoporosis injectable in the U.S.
You may also be interested in...
Denosumab Uptake Could Depend On Abating Physicians’ Financial Risk
If denosumab is approved, Amgen may need to provide physicians with a shield against the financial risk of stocking the injectable osteoporosis treatment in their offices
Amgen’s Positive Denosumab Pivotal Trial Reduces Overhangs For Firm
Big biotech needs the potential $2.4 billion analysts estimate the bone-building drug could bring by 2016.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.